Mekinist Adverse Event Report 2018

$19.99

This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions

Description

Mekinist (trametinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Mekinist is used alone or in combination with another medicine called dabrafenib (Tafinlar) to treat certain types of cancer in people who have a “BRAF” gene mutation. Mekinist is for use in treating: melanoma (skin cancer) that cannot be treated with surgery or has spread to other parts of the body, or to prevent melanoma from coming back after surgery;, non-small cell lung cancer that has spread to other parts of the body; or, advanced or metastatic thyroid cancer that has spread and for which there are no other treatment options.https://www.drugs.com/mekinist.html